X

Trial Profile

Non-small Cell Lung Cancer: The Impact of Ethnic Origin on Patients Being Treated Second Line With Pemetrexed - An Observational Study.

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 14 Jan 2020

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Pemetrexed (Primary)
Indications Non-small cell lung cancer
Focus Therapeutic Use
Sponsors Eli Lilly and Company

Most Recent Events

15 Mar 2012 Actual patient numbers amended from 685 to 434 as reported by ClinicalTrials.gov.
16 Jun 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
02 Jun 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com